Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation

Michael Chavez1, Matthew T. Silvestrini1, Elizabeth S. Ingham1, Brett Z. Fite1, Lisa M. Mahakian1, Sarah M. Tam1, Asaf Ilovitsh1, Arta M. Monjazeb2, William J. Murphy3, Neil E. Hubbard4, Ryan R. Davis5, Clifford G. Tepper5, Alexander D. Borowsky4, Katherine W. Ferrara1 1University of California, Davis, Department of Biomedical Engineering, 451 Health Sciences Drive, Davis, CA 95616, USA, 2University of California, Davis, Department of Radiation Oncology, 4501 X Street, Sacramento, CA 95817, 3University of California, Davis, Department of Dermatology, 2921 Stockton Blvd., Institute for Regenerative Cures, Suite 1630, Sacramento, CA 95817, USA, 4University of California, Davis, Center for Comparative Medicine, Davis, CA 95616, USA, 5University of California, Davis School of Medicine, Department of Biochemistry and Molecular Medicine, 4645 Second Avenue, Sacramento, CA 95817, USA